Septerna (NASDAQ:SEPN) Hits New 1-Year Low – Here’s Why

Septerna, Inc. (NASDAQ:SEPN)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $12.17 and last traded at $11.88, with a volume of 12510 shares traded. The stock had previously closed at $13.09.

Wall Street Analysts Forecast Growth

SEPN has been the topic of a number of recent research reports. JPMorgan Chase & Co. began coverage on shares of Septerna in a report on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price objective on shares of Septerna in a research note on Tuesday. TD Cowen assumed coverage on shares of Septerna in a research note on Tuesday, November 19th. They issued a “buy” rating for the company. Finally, Wells Fargo & Company started coverage on Septerna in a report on Tuesday, November 19th. They set an “overweight” rating and a $43.00 price objective on the stock.

Septerna Trading Down 3.4 %

The company’s fifty day simple moving average is $20.17.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. purchased a new stake in shares of Septerna during the fourth quarter valued at approximately $871,000. Vanguard Group Inc. purchased a new position in Septerna in the 4th quarter valued at about $22,557,000. Corebridge Financial Inc. acquired a new stake in shares of Septerna during the fourth quarter valued at about $212,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Septerna during the fourth quarter worth about $3,197,000. Finally, PNC Financial Services Group Inc. purchased a new position in Septerna in the fourth quarter valued at about $61,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.